A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women.

Trial Profile

A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Estetrol (Primary)
  • Indications Vasomotor symptoms
  • Focus Therapeutic Use
  • Acronyms E4 RELIEF
  • Sponsors Donesta Bioscience
  • Most Recent Events

    • 08 Feb 2017 Planned end date changed from 1 Dec 2016 to 1 Feb 2018.
    • 08 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2018.
    • 30 Apr 2016 Status changed from planning to recruiting, as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top